Vancomycin: What dosages are needed to achieve efficacy in paediatric hematology/oncology?;Vancomycine: Quelles doses pour une meilleure efficacité en hémato-oncologie pédiatrique?

Archives de Pediatrie

Volumn 18, Issue 8, 2011, Pages 850-855

  Zegbeh, H ^a   Bleyzac, N ^a   Berhoune, C ^a   Bertrand, Y ^a  

^a Institut d'Hematologie et d'Oncologie Pediatrique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BAYES THEOREM; CHILD; CHILDHOOD CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; HEMATOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; REACTION OPTIMIZATION; SCHOOL CHILD; STEADY STATE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG DOSAGE CALCULATIONS; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 79960584505     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2011.05.013     Document Type: Article

References (30)

1. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 2004, 32:315-327.
2. Howden B.P. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). Intern Med J 2005, 35(Suppl 2):136-140.
3. Shorr A.F. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007, 45(Suppl 3):171-176.
4. Rybak M.J., Lomaestro B.M., Rotschafer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
5. Taieb F., Le Monnier A., Bille E., et al. Optimisation de la prescription de la vancomycine: étude prospective observationnelle dans un centre hospitalo-universitaire parisien. Med Mal Infect 2010, 40:273-278.
6. Jelliffe R.W., Schumitzky A., Bayard D., et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new " multiple model" dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet 1998, 34:57-77.
7. Wrishko R.E., Levine M., Khoo D., et al. Vancomycin pharmacokinetics and Bayesian estimation in paediatric patients. Ther Drug Monit 2000, 22:522-531.
8. Pea F., Bertolissi M., Di Silvestre A., et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimising vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002, 20:326-332.
9. Buelga D.S., Fernández de Gatta M.D.M., Herrera E.V., et al. Population pharmacokinetic analysis of vancomycin in patients with haematological malignancies. Antimicrob Agents Chemother 2005, 49:4934-4941.
10. Sadoh S., Tsuji Y., Tsukamoto K. Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies. Yakugaku Zasshi 2010, 130:69-73.
11. Omote S., Yano Y., Hashida T., et al. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull 2009, 32:99-104.
12. James J.K., Palmer S.M., Levine D.P., et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996, 40:696-700.
13. Kasiakou S.K., Sermaides G.J., Michalopoulos A., et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:581-589.
14. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467.
15. Luer M.S., Neill K.K., Gurley B.J., et al. Fluctuations in vancomycin CNS tissue concentrations following intermittent and continuous infusions in the rat. Neurol Res 2004, 26:312-315.
16. Carricajo A., Forgeot A., Morel J., et al. Ajustement de la posologie de la vancomycine administrée en perfusion continue chez des patients de réanimation. Ann Fr Anesth Reanim 2010, 29:55-57.
17. Bourguignon L., Goutelle S., Bertrand N., et al. Pharmacocinétique/pharmacodynamie, clinique des antibiotiques. Précis de bactériologie clinique 2007, ESKA, Paris. J. Freney, F. Renaud, R. Leclercq, P. Riegel (Eds.).
18. Miles M.V., Li L., Lakkis H., et al. Special considerations for monitoring vancomycin concentrations in podiatric patients. Ther Drug Monit 1997, 19:265-270.
19. Mariani-Kurkdjian P., Nebbad H., Aujard Y., et al. Surveillance des taux sériques de vancomycine dans le traitement des infections à staphylocoque en pédiatrie. Arch Pediatr 2008, 15:1625-1629.
20. Schwartz G.J., Brion L.P., Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987, 34:571-590.
21. *PACK PC programs for population pharmacokinetic modelling, modelling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care 1991:922-4. PMID: 1807753 [PubMed - indexed for Medline], PMCID: PMC2247677.
22. Thomson A.H., Staatz C.E., Tobin C.M., et al. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009, 63:1050-1057.
23. Ingram P.R., Lye D.C., Tambyah P.A., et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008, 62:168-171.
24. Bingen E., Mariani-Kurkdjian P., Nebbad B. Comment optimiser le taux sérique de vancomycine dans le traitement des infections à Staphylococcus aureus?. Med Mal Infect 2006, 36:439-442.
25. Frymoyer A., Hersh A.L., Benet L.Z., et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009, 28:398-402.
26. Yamamoto M., Kuzuya T., Baba H., et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther 2009, 34:473-483.
27. Fernández de Gatta M.D.M., Santos Buelga D., Sánchez Navarro A., et al. Vancomycin dosage optimisation in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009, 48:273-280.
28. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995, 14:667-673.
29. Asbury W.H., Darsey E.H., Rose W.B., et al. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993, 27:490-496.
30. Pawlotsky F., Thomas A., Kergueris M.F., et al. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol 1998, 46:163-167.